Kratochwil C, Haberkorn U, Giesel F L
Abteilung für Nuklearmedizin, Universitätsklinikum Heidelberg, 69120, Heidelberg, Deutschland.
Radiologe. 2010 Aug;50(8):684-91. doi: 10.1007/s00117-009-1960-6.
With the introduction of positron emission tomography (PET) and more recently the hybrid systems PET/CT, the management of cancer patients in the treatment strategy has changed tremendously. The combination of PET with multidetector CT scanning enables the integration of metabolic and high resolution morphological image information. PET/CT is nowadays an established modality for tumor detection, characterization, staging and response monitoring. The increased installation of PET/CT systems worldwide and also the increased scientific publications underline the importance of this imaging modality. PET/CT is particular the imaging modality of choice in lung cancer staging and re-staging (T, N and M staging). The possible increased success of surgery in lung cancer patients and also the expected reduction in additional invasive diagnostics lead to benefits for both the individual patient and the healthcare system. In this review article PET and PET/CT is presented for diagnostic and therapeutic stratification in lung cancer. The fundamentals of glucose metabolism, staging, tumor recurrence and therapeutic monitoring are presented.
随着正电子发射断层扫描(PET)以及最近PET/CT混合系统的引入,癌症患者在治疗策略中的管理发生了巨大变化。PET与多排CT扫描相结合,能够整合代谢和高分辨率形态学图像信息。如今,PET/CT已成为肿瘤检测、特征描述、分期及疗效监测的既定模式。全球范围内PET/CT系统安装量的增加以及科学出版物数量的增多,都凸显了这种成像模式的重要性。PET/CT尤其适用于肺癌分期及再分期(T、N和M分期)。肺癌患者手术成功率的可能提高以及额外侵入性诊断预期的减少,对个体患者和医疗保健系统都有益处。在这篇综述文章中,介绍了PET和PET/CT在肺癌诊断及治疗分层中的应用。阐述了葡萄糖代谢、分期、肿瘤复发及治疗监测的基本原理。